### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Duchemin Jeffrey.						2. Issuer Name and Ticker or Trading Symbol HARVARD BIOSCIENCE INC [ HBIO ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					111	11( ) /	пп	DIO	OCILI	TOL	<u> </u>	וטוו			X	Direc	ctor	1	0% C	wner
(Last)	(F	irst) (	) (Middle)					Date of Earliest Transaction (Month/Day/Year)									er (give title w)		ther elow)	(specify
HARVARD BIOSCIENCE, INC.						05/25/2014									Chief Executive Officer					
84 OCTOBER HILL ROAD																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)															ine)  X Form filed by One Reporting Person					
HOLLISTON MA 01746															Λ	Form filed by More than One Reporting				
(0.1)					1										Person					
(City)	(S	tate) (	Zip)																	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Date,						ies Acquired (A) ( Of (D) (Instr. 3, 4			and 5) Secu Bene Own		icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
							v	Amount		(A) or (D)	Price	,	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock 05/25/2						2017			A		357,609	<b>)</b> (1)	A	\$0.00		0 788,984 <sup>(2)</sup>		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deen Execution if any (Month/D	n Date,	4. Transa Code ( 8)		of		6. Date E Expiration (Month/I	on Dat		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)				rr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nun of	ount nber ıres						

### **Explanation of Responses:**

- 1. Represents a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021.
- 2. Includes (a) a deferred stock award of 357,609 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 218,750 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (c) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (d) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (f) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (f) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (f) a deferred stock award of 34,450 restricted stock units which shall vest in two equal installments on January 1, 2018, 2019 and 2020; (f) a deferred stock award of 34,450 restricted stock units which shall vest in two equal i 2018 and 2019; (d) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (e) 106,427 shares of common stock held by the Reporting Person.

### Remarks:

This form has been signed under power of attorney.

/s/ Chad Porter, by power of 05/30/2017 attornev

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.